Scholarlink

Background <p>Interstitial lung diseases (ILDs) are progressive chronic lung diseases associated with poor prognosis despite available disease-modifying therapy. Reported incidence and prevalence of ILD varies, and few studies have described epidemiology across the range of ILD subtypes in complete population-based cohorts. This study aimed to estimate incidence and prevalence of ILD, overall and by subtype, in a complete nationwide cohort from Norway.</p> Methods <p>The Norwegian Patient Registry and Norwegian Prescribed Drug Registry were used to identify all patients with diagnosis codes identifying an ILD between 2011 and 2023. Using diagnosis code-based algorithms adapted from previous studies, the incidence and prevalence of ILD subtypes was estimated overall by year, and by subgroups defined by age and sex.</p> Results <p>Using a broad definition, the overall prevalence of ILD in Norway has increased to over 450 cases per 100,000 from 2012 to 2023. The prevalence of idiopathic pulmonary fibrosis (IPF) has increased to 46 per 100,000 and prevalence of connective tissue disease related ILD (CTD-ILD) has increased to nearly 42 per 100,000. Current estimates of incidence ranged from about 1 per 100,000 for hypersensitivity pneumonitis, to about 5 per 100,000 for CTD-ILD, to 8–10 per 100,000 for IPF.</p> Conclusions <p>Incidence and prevalence of ILDs in Norway are comparable to published reports from other regions. The prevalence of ILDs in Norway appears to be increasing substantially.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Incidence and prevalence of interstitial lung diseases in Norway: analysis of the national Norwegian patient registry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月21日

查看全文
  • Michael T. Durheim,
  • Phuong Phuong Diep,
  • Sandre S. Lirhus,
  • Tomas M. L. Eagan

摘要

Background

Interstitial lung diseases (ILDs) are progressive chronic lung diseases associated with poor prognosis despite available disease-modifying therapy. Reported incidence and prevalence of ILD varies, and few studies have described epidemiology across the range of ILD subtypes in complete population-based cohorts. This study aimed to estimate incidence and prevalence of ILD, overall and by subtype, in a complete nationwide cohort from Norway.

Methods

The Norwegian Patient Registry and Norwegian Prescribed Drug Registry were used to identify all patients with diagnosis codes identifying an ILD between 2011 and 2023. Using diagnosis code-based algorithms adapted from previous studies, the incidence and prevalence of ILD subtypes was estimated overall by year, and by subgroups defined by age and sex.

Results

Using a broad definition, the overall prevalence of ILD in Norway has increased to over 450 cases per 100,000 from 2012 to 2023. The prevalence of idiopathic pulmonary fibrosis (IPF) has increased to 46 per 100,000 and prevalence of connective tissue disease related ILD (CTD-ILD) has increased to nearly 42 per 100,000. Current estimates of incidence ranged from about 1 per 100,000 for hypersensitivity pneumonitis, to about 5 per 100,000 for CTD-ILD, to 8–10 per 100,000 for IPF.

Conclusions

Incidence and prevalence of ILDs in Norway are comparable to published reports from other regions. The prevalence of ILDs in Norway appears to be increasing substantially.